BackFreeline Therapeutics Holdings plc Overview

Freeline Therapeutics Holdings plc Net Tangible Assets

Track Freeline Therapeutics Holdings plc's net tangible assets ($30M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Net Tangible Assets
$30.04M
56.20% YoYΔ $-38.54M vs prior year quarter

Peer average

Loading

Freeline Therapeutics Holdings plc Net Tangible Assets History

Loading

Freeline Therapeutics Holdings plc vs. peers: Net Tangible Assets Comparison

Loading

Freeline Therapeutics Holdings plc Net Tangible Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Freeline Therapeutics Holdings plc (FRLN) FAQ

Freeline Therapeutics Holdings plc's net tangible assets stands at $30M as of September 2023. That compares with $69M in the prior-year period — down 56.2% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Freeline Therapeutics Holdings plc reported $30M in net tangible assets versus $69M a year earlier — a 56.2% year-over-year decrease. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $69M in the prior-year period — down 56.2% year over year. Sustained growth in net tangible assets can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Freeline Therapeutics Holdings plc's net tangible assets evolved across reporting periods, while the comparison chart places FRLN next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, net tangible assets is commonly used to spot outliers. Freeline Therapeutics Holdings plc's reading of $30M is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.